Last reviewed · How we verify
NCT06850246
Safety and Effectiveness of High Frequency Electrocautery for Abdominal Fat Reduction
NA trial testing treatment of radiofrequency technology in BMI in 30 participants. Participants enrolled and being followed up; not accepting new ones.
1 February 2025
Quick facts
| Lead sponsor | Chinese Medical Association |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | single group |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 1 July 2024 |
| Primary completion | 1 February 2025 |
| Estimated completion | 1 April 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- treatment of radiofrequency technology
- Placebo
Conditions studied
- BMI — all drugs for BMI →
Sponsor
Chinese Medical Association
Who can join
Adults 18 to 65, any sex, with BMI. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to learn if the intervention of radiofrequency technology can help treat abdominal fat hypertrophy and skin laxity in adults. The main questions it aims to answer are * Does radiofrequency technology lower the abdominal subcutaneous adipose tissue height by ultrasound measurement? * Does radiofrequency technology improve abdominal circumference data and lower the number of times participants need to use a rescue inhaler. Researchers will compare the treatment side to the non-treatment side to see if radiofrequency technology works to treat abdominal fat hypertrophy and skin laxity? Participants will: * Accept the treatment of radiofrequency technology every week for 10 weeks. * Visit the clinic 1 month and 3 months after the treatment ends for checkups and tests.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06850246
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for BMI
Currently open trials in the same condition.
- NCT06420817 — Effect of a Customised Lifestyle Medicine Strategy on Lowering Blood Lipid Levels in Indian Physicians · NA · active not recruiting
Other Chinese Medical Association trials
Trials by the same sponsor.
- NCT07415473 — Akkermansia Muciniphila Combined With Infliximab for Promoting Intestinal Mucosal Healing in Crohn's Disease · Phase 4 · not yet recruiting
- NCT07417696 — Palmitoleic Acid Combined With Infliximab for Promoting Intestinal Mucosal Healing in Crohn's Disease · Phase 4 · not yet recruiting
- NCT05143593 — Species-specific Bacterial Detector for Fast Pathogen Diagnosis of Severe Pneumonia · NA · not yet recruiting
- NCT07037264 — A Study of the Efficacy and Safety of Non-ablative Fractional Laser in the Treatment of Thyroidectomy Scars · NA · enrolling by invitation
- NCT07251764 — The Blood-Interstitial Glucose Gap · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06850246 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chinese Medical Association
- Last refreshed: 3 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06850246.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing